中华放射学杂志
中華放射學雜誌
중화방사학잡지
Chinese Journal of Radiology
2014年
3期
215-218
,共4页
何为%刘毅%刘剑羽%陆敏
何為%劉毅%劉劍羽%陸敏
하위%류의%류검우%륙민
前列腺肿瘤%磁共振成像%病理学
前列腺腫瘤%磁共振成像%病理學
전렬선종류%자공진성상%병이학
Prostate neoplasms%Magnetic resonance imaging%Pathology
目的 探讨3.0 T MR动态增强扫描(DCE-MRI)定量分析诊断前列腺癌,尤其是中央腺体癌的价值.方法 回顾性分析行前列腺DCE-MRI检查,并经前列腺根治术后病理证实的26例患者资料.将前列腺根治标本制成前列腺病理大切片,根据病理标本的分区定位标准及结果,在DCE-MRI定量参数图上分别测量前列腺相应部位的转运常数(Ktrans)、血管外细胞外间隙体积百分数(Ve)及速率常数(kep).对中央腺体癌区、中央腺体非癌区、外周带癌区及外周带非癌区的各定量参数值分别进行Kruskal-Wallis H检验,各参数值的组内两两比较采用Mann-Whitney U检验.结果 26例前列腺癌共获得可评估前列腺分区468个,其中中央腺体癌区115个、中央腺体非癌区142个、外周带癌区68个、外周带非癌区143个.前列腺癌呈明显多灶性分布.中央腺体癌区的Ktrans、kep、Ve值分别为(1.04 ±0.26)/min、(1.43±0.46)/min和0.76 ±0.12,中央腺体非癌区分别为(0.82±0.19)/min、(1.12±0.26)/min、0.75±0.14,外周带癌区分别为(0.95±0.31)/min、(1.31±0.51)/min和0.76±0.13,外周带非癌区分别为(0.32±0.07)/min、(0.52±0.13)/min和0.64±0.14,各参数值组间差异均有统计学意义(x2值分别为316.008、297.985、63.681,P值均＜0.01).Ktrans、Kep值组内两两比较,前列腺癌区均高于非癌区(P＜0.05).结论 DCE-MRI定量参数有助于前列腺癌灶,包括中央腺体癌灶的诊断.
目的 探討3.0 T MR動態增彊掃描(DCE-MRI)定量分析診斷前列腺癌,尤其是中央腺體癌的價值.方法 迴顧性分析行前列腺DCE-MRI檢查,併經前列腺根治術後病理證實的26例患者資料.將前列腺根治標本製成前列腺病理大切片,根據病理標本的分區定位標準及結果,在DCE-MRI定量參數圖上分彆測量前列腺相應部位的轉運常數(Ktrans)、血管外細胞外間隙體積百分數(Ve)及速率常數(kep).對中央腺體癌區、中央腺體非癌區、外週帶癌區及外週帶非癌區的各定量參數值分彆進行Kruskal-Wallis H檢驗,各參數值的組內兩兩比較採用Mann-Whitney U檢驗.結果 26例前列腺癌共穫得可評估前列腺分區468箇,其中中央腺體癌區115箇、中央腺體非癌區142箇、外週帶癌區68箇、外週帶非癌區143箇.前列腺癌呈明顯多竈性分佈.中央腺體癌區的Ktrans、kep、Ve值分彆為(1.04 ±0.26)/min、(1.43±0.46)/min和0.76 ±0.12,中央腺體非癌區分彆為(0.82±0.19)/min、(1.12±0.26)/min、0.75±0.14,外週帶癌區分彆為(0.95±0.31)/min、(1.31±0.51)/min和0.76±0.13,外週帶非癌區分彆為(0.32±0.07)/min、(0.52±0.13)/min和0.64±0.14,各參數值組間差異均有統計學意義(x2值分彆為316.008、297.985、63.681,P值均＜0.01).Ktrans、Kep值組內兩兩比較,前列腺癌區均高于非癌區(P＜0.05).結論 DCE-MRI定量參數有助于前列腺癌竈,包括中央腺體癌竈的診斷.
목적 탐토3.0 T MR동태증강소묘(DCE-MRI)정량분석진단전렬선암,우기시중앙선체암적개치.방법 회고성분석행전렬선DCE-MRI검사,병경전렬선근치술후병리증실적26례환자자료.장전렬선근치표본제성전렬선병리대절편,근거병리표본적분구정위표준급결과,재DCE-MRI정량삼수도상분별측량전렬선상응부위적전운상수(Ktrans)、혈관외세포외간극체적백분수(Ve)급속솔상수(kep).대중앙선체암구、중앙선체비암구、외주대암구급외주대비암구적각정량삼수치분별진행Kruskal-Wallis H검험,각삼수치적조내량량비교채용Mann-Whitney U검험.결과 26례전렬선암공획득가평고전렬선분구468개,기중중앙선체암구115개、중앙선체비암구142개、외주대암구68개、외주대비암구143개.전렬선암정명현다조성분포.중앙선체암구적Ktrans、kep、Ve치분별위(1.04 ±0.26)/min、(1.43±0.46)/min화0.76 ±0.12,중앙선체비암구분별위(0.82±0.19)/min、(1.12±0.26)/min、0.75±0.14,외주대암구분별위(0.95±0.31)/min、(1.31±0.51)/min화0.76±0.13,외주대비암구분별위(0.32±0.07)/min、(0.52±0.13)/min화0.64±0.14,각삼수치조간차이균유통계학의의(x2치분별위316.008、297.985、63.681,P치균＜0.01).Ktrans、Kep치조내량량비교,전렬선암구균고우비암구(P＜0.05).결론 DCE-MRI정량삼수유조우전렬선암조,포괄중앙선체암조적진단.
Objective To investigate the diagnostic value of the quantitative analysis parameters of dynamic contrast-enhanced MRI (DCE-MRI) for prostate cancer.Methods MR examination were performed in 26 patients and correlations were made with surgical pathology following radical prostatectomy.According to the localization of pathologic specimens,ROI were drawn on areas of cancerous regions,noncancerous regions in peripheral zone and central gland to measure the values of Ktrans,kep and Ve.The values of the three parameters in different tissue were compared with Kruskal-Wallis H and Mann-Whitney U.Results Twenty six patients had prostate cancer confirmed by pathology.Data from 468 assessable regions of prostate were acquired,including 115 cancerous regions and 142 noncancerous regions in central gland,68 cancerous regions and 143 noncancerous regions in peripheral zone.Prostate cancer showed a multifocal distribution.The K,kep and Ve values were (1.04 ± 0.26)/min,(1.43 ± 0.46)/min,(0.76 ±0.12) respectively for cancerous regions in central gland,and (0.82 ±0.19)/min,(1.12 ±0.26)/min,(0.75 ± 0.14) respectively for noncancerous regions in central gland,(0.95 ±0.31)/min,(1.31 ±0.51)/min,(0.76 ± 0.13) respectively for cancerous regions in peripheral zone and (0.32 ± 0.07)/min,(0.52 ± 0.13)/min,(0.64 ± 0.14) respectively for noncancerous regions in peripheral zone.The differences among the three parameters were statistically significant (x2 =316.008,297.985,63.681,P ＜0.01).The Ktrans,kep values of cancerous regions were significantly higher than the corresponding values of noncancerous regions,respectively.Conclusion Quantitative analysis parameters of DCE-MRI contribute to the diagnosis of prostate cancer,including cancer located in central gland.
